Search the Newsreel

Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday

OncoSil Medical Slips as Its Pancreatic Cancer Device Reaches the FDA's Door

Concord Biotech to Hold Q1FY27 Earnings Call on August 3 at 3:30 PM IST

The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call

The Oncology Institute, Inc. (TOI) announced that it will release its second quarter 2026 financial results on Thursday, August 6, 2026. This will be followed by a conference call at 5:00 p.m. (Eastern Time) on the same day. Interested parties can access the call …

Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Oncolytics Biotech Inc (ONCY). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page presents general stock information for ONCY, including its market …

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with …

About 81% of BOND-003 patients maintained their bladders at 24 months

CG Oncology (NASDAQ: CGON) announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology. The study evaluated cretostimogene grenadenorepvec monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer and met its primary endpoint with a 75.5% complete response rate. …

Champions Oncology outlines fiscal 2027 plan with Corellia fully funded as it reports $59.4M revenue and $1.6M adjusted EBITDA

Earnings Call Insights: Champions Oncology (CSBR) Q4 fiscal 2026 MANAGEMENT VIEW * CEO Robert Brainin said the company delivered “record annual revenue” and “met our commitment to full year positive adjusted EBITDA,” including “positive adjusted EBITDA in each of the 4 quarters on its …

CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary

Champions Oncology, Inc. reported fiscal year 2026 revenue of $59.43 million, a 4.4% increase from the prior year, driven by higher pharmacology services and conversion of delayed studies. Despite revenue growth, the company experienced a net loss of ($1.18M) and diluted EPS of ($0.08), …

Champions Oncology Reports Record Annual Revenue of $59 Million

Champions Oncology, Inc. announced record annual revenue of $59.4 million for fiscal year 2026, alongside its fourth consecutive quarter of positive Adjusted EBITDA. The company highlighted significant progress in strategic priorities, including expanding its radiopharmaceutical platform and strengthening its data strategy, which it believes …

BlackRock, Inc. (CGON) discloses 6.8% beneficial ownership in CG Oncology

BlackRock, Inc. has filed an amended Schedule 13G disclosing a 6.8% beneficial ownership in CG Oncology (CGON), amounting to 6,023,696 shares of common stock. BlackRock holds sole voting power over 5,914,671 shares and sole dispositive power over all 6,023,696 shares. The filing specifies that …

Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026

Champions Oncology (CSBR) reported record fiscal year 2026 revenue of $59.4 million and positive adjusted EBITDA of $1.6 million for the full year. Despite these gains, the company posted a net loss due to continued investments in radiopharmaceuticals, its data platform, and commercial expansion. …

BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A

BlackRock, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 863,259 shares of Cardiff Oncology, Inc. common stock, which represents a 1.3% stake in the company. BlackRock exercises sole voting and dispositive power over these shares, and the filing clarifies that no …

BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO)

BlackRock, Inc. has filed a Schedule 13G, disclosing a passive ownership of 5.4% in ALX Oncology Holdings Inc. This stake amounts to 7,327,850 common shares, with BlackRock exercising sole voting power over 7,231,560 shares and sole dispositive power over all beneficially owned shares. The …

At fiscal year-end, Champions Oncology had $4.9M cash, no debt

Champions Oncology (CSBR) reported record fiscal 2026 revenue of $59.4 million, up 4% year-over-year, despite missing prior-year data license revenue. The company ended the fiscal year with $4.9 million in cash and no debt, while achieving positive Adjusted EBITDA in all four quarters. Operating …

CGON (CGON) filer discloses 50,000-share sale plan and recent stock sales

An affiliate of CG Oncology (CGON), Ambaw Bellete, has filed a notice to sell 50,000 shares of common stock, valued at $3,627,995.00, through a stock option exercise on July 27, 2026. The filing also reports prior sales by the same individual, including 50,000 shares …

H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40

H.C. Wainwright has reiterated its Buy rating for Kura Oncology (KURA.US), maintaining a target price of $40. This suggests a continued positive outlook on the company's stock performance.

Concord Medical Services Holdings Ltd (CCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Concord Medical Services Holdings Ltd (CCM), detailing its support, resistance, indicators, and moving averages. It presents various technical indicator values and directions, alongside moving average signals, to offer a comprehensive overview of the stock's current technical status. …

ALX Oncology Holdings Inc (ALXO) Cash Flow

This article provides a detailed cash flow statement for ALX Oncology Holdings Inc (ALXO), covering quarterly and annual data with year-over-year changes across operating, investing, and financing activities. It breaks down various components such as net income, changes in working capital, capital expenditures, and …

Pyxis Oncology Inc (PYXS) Balance Sheet

This article provides a detailed balance sheet for Pyxis Oncology Inc (PYXS), presenting both quarterly and annual financial data. It allows users to assess the company's financial health, examine fundamentals, and calculate key financial ratios related to liquidity, leverage, and return on equity. The …

The Oncology Institute's Q2 results call will stream online Aug. 6

The Oncology Institute (NASDAQ: TOI) announced it will release its second-quarter 2026 financial results on Thursday, August 6, 2026. A conference call will follow on the same day at 5:00 p.m. Eastern Time, accessible via dial-in numbers or a live webcast on the company’s …

Oncology Institute Inc (TOI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Oncology Institute Inc (TOI), listing major individual and institutional holders and their respective proportions. It also provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity, alongside related ETF holdings. Key insights …

Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice

Oncolytics Biotech Inc. (ONCY) was granted FDA Fast Track designation for pelareorep in combination with a checkpoint inhibitor for 2L+ squamous cell anal cancer, based on promising results from the GOBLET study. Despite this positive development, the company received a Nasdaq compliance notice for …

CCM|Concord Medical Services Holdings Ltd|Price:4.300|Chg%:+0.080

This article provides a detailed financial overview of Concord Medical Services Holdings Ltd (CCM), including its stock performance, financial statements, and key financial indicators. It highlights the company's revenue, net profit, assets, and liabilities, along with year-on-year changes and upcoming earnings information. The report …

Oncology Institute Inc (TOI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Oncology Institute Inc (TOI), detailing its business segments for FY2025. Key revenue streams include Dispensary revenue, FFS revenue, Capitated revenue, and Clinical research trials and other revenue, with dispensary revenue forming the largest proportion. The data presented …

Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma

Kura Oncology announced positive Phase 1a results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). The combination therapy demonstrated response rates up to 50% and a median progression-free survival of 13 months, along …

Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial

Kura Oncology announced positive Phase 1a results for its darlifarnib-cabozantinib combination therapy in advanced clear cell renal cell carcinoma, showing up to a 50% response rate and durable tumor shrinkage. The company is currently enrolling for a randomized Phase 1b study to determine the …

Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pyxis Oncology Inc. (PYXS), outlining its major shareholders, investor types, and institutional holdings. It provides a breakdown of proportions held by entities like Pfizer Inc., Laurion Capital Management LP, and various categories such as hedge funds and …

Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pyxis Oncology Inc's (PYXS) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and offers no dividend data. The article also presents current stock performance data and …

Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Champions Oncology Inc (CSBR), outlining major institutional and individual holdings. It lists the top shareholders, the proportion of shares held by different investor types, and historical institutional shareholding data. The data indicates significant holdings by Battery Management …

Octagon Capital Advisors LP Sells 324,110 Shares of BridgeBio Oncology Therapeutics, Inc $BBOT

Octagon Capital Advisors LP has reduced its stake in BridgeBio Oncology Therapeutics (NASDAQ:BBOT) by 31.1%, selling 324,110 shares but still holding 719,000 shares valued at approximately $6.44 million. Despite institutional selling, analysts generally maintain a "Moderate Buy" rating with an average price target of …

2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC

Orbimed Advisors LLC purchased 2.87 million shares of ALX Oncology Holdings Inc. ($ALXO) in the first quarter, a stake valued at approximately $5.75 million. This acquisition makes Orbimed Advisors LLC the owner of about 2.13% of ALX Oncology. Other institutional investors collectively hold 97.97% …

Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Citius Oncology Inc (CTOR) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits. The piece presents …

Champions Oncology (NASDAQ:CSBR) Releases Earnings Results, Hits Estimates

Champions Oncology earnings beat by $0.06, revenue topped estimates

Concord Medical Services Holdings Ltd (CCM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Concord Medical Services Holdings Ltd (CCM) stock. It details the company's dividend history, noting that no dividends have been distributed in the past five years, and lists recent stock split events, all recorded as a 10-for-1 merger on …